Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial.
Carles J, Alonso-Gordoa T, Mellado B, Méndez-Vidal MJ, Vázquez S, González-Del-Alba A, Piulats JM, Borrega P, Gallardo E, Morales-Barrera R, Paredes P, Reig O, Garcías de España C, Collado R, Bonfill T, Suárez C, Sampayo-Cordero M, Malfettone A, Garde J. Carles J, et al. Eur J Cancer. 2022 Sep;173:317-326. doi: 10.1016/j.ejca.2022.06.057. Epub 2022 Aug 16. Eur J Cancer. 2022. PMID: 35981452 Free article. Clinical Trial.
Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases.
Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Malfettone A, Pérez-García J, Llombart-Cussac A, Cortés J, Moltó-Abad M, Muñoz-Delgado C, Pérez-Quintana M, Pérez-López J. Sampayo-Cordero M, et al. Orphanet J Rare Dis. 2019 Oct 21;14(1):230. doi: 10.1186/s13023-019-1202-6. Orphanet J Rare Dis. 2019. PMID: 31639024 Free PMC article.
The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II).
Sampayo-Cordero M, Miguel-Huguet B, Malfettone A, Pérez-García JM, Llombart-Cussac A, Cortés J, Pardo A, Pérez-López J. Sampayo-Cordero M, et al. Int J Environ Res Public Health. 2020 Sep 10;17(18):6590. doi: 10.3390/ijerph17186590. Int J Environ Res Public Health. 2020. PMID: 32927819 Free PMC article.
Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial.
López-Miranda E, Pérez-García JM, Di Cosimo S, Brain E, Ravnik M, Escrivá-de-Romaní S, Vidal M, Gligorov J, Borštnar S, Calabuig L, Sampayo-Cordero M, Malfettone A, Llombart-Cussac A, Suter TM, Cortés J. López-Miranda E, et al. Cancers (Basel). 2020 Nov 25;12(12):3509. doi: 10.3390/cancers12123509. Cancers (Basel). 2020. PMID: 33255658 Free PMC article.
Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design.
Sampayo-Cordero M, Miguel-Huguet B, Pérez-García J, Páez D, Guerrero-Zotano ÁL, Garde-Noguera J, Aguirre E, Holgado E, López-Miranda E, Huang X, Malfettone A, Llombart-Cussac A, Cortés J. Sampayo-Cordero M, et al. Contemp Clin Trials Commun. 2020 Nov 28;20:100678. doi: 10.1016/j.conctc.2020.100678. eCollection 2020 Dec. Contemp Clin Trials Commun. 2020. PMID: 33336109 Free PMC article.
Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.
Pérez-García JM, Llombart-Cussac A, G Cortés M, Curigliano G, López-Miranda E, Alonso JL, Bermejo B, Calvo L, Carañana V, de la Cruz Sánchez S, M Vázquez R, Prat A, R Borrego M, Sampayo-Cordero M, Seguí-Palmer MÁ, Soberino J, Malfettone A, Schmid P, Cortés J. Pérez-García JM, et al. Eur J Cancer. 2021 May;148:382-394. doi: 10.1016/j.ejca.2021.02.028. Epub 2021 Mar 29. Eur J Cancer. 2021. PMID: 33794440 Clinical Trial.
Nobody dares stopping clinical research, not even COVID-19.
Malfettone A, Di Cosimo S, Pérez-García JM, García A, Sampayo-Cordero M, Mina L, Herrero C, Llombart-Cussac A, Cortés J. Malfettone A, et al. NPJ Breast Cancer. 2021 Apr 8;7(1):39. doi: 10.1038/s41523-021-00249-1. NPJ Breast Cancer. 2021. PMID: 33833237 Free PMC article.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A; PHERGain steering committee and trial investigators. Pérez-García JM, et al. Lancet Oncol. 2021 Jun;22(6):858-871. doi: 10.1016/S1470-2045(21)00122-4. Epub 2021 May 18. Lancet Oncol. 2021. PMID: 34019819 Clinical Trial.
The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: "The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis".
Sampayo-Cordero M, Miguel-Huguet B, Malfettone A, Pérez-García JM, Llombart-Cussac A, Cortés J, Pardo A, Pérez-López J. Sampayo-Cordero M, et al. Front Mol Biosci. 2021 Jun 22;8:690615. doi: 10.3389/fmolb.2021.690615. eCollection 2021. Front Mol Biosci. 2021. PMID: 34239895 Free PMC article. Review.
31 results